B01AC23 • cilostazol • Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin
Cilostazol is a phosphodiesterase III inhibitor used for the treatment of intermittent claudication, a condition characterized by leg pain during walking due to insufficient blood flow. It improves blood flow by dilating blood vessels and inhibiting platelet aggregation.
The medication is taken orally, usually twice daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and avoid consuming grapefruit during treatment, as it may interfere with the drug's metabolism.
Patients should be aware of potential side effects, such as headaches, dizziness, or palpitations. It is important to inform the doctor of any unusual symptoms.
Common side effects include headaches, dizziness, diarrhea, and palpitations. In rare cases, severe reactions such as bleeding or allergic reactions may occur. Patients should be informed of these risks before starting treatment.
Substance: cilostazol
Date of last drug list: 01-06-2020
Commercial code: W60706003
Concentration: 50mg
Pharmaceutical form: tablets
Quantity: 98
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: EGIS PHARMACEUTICALS PLC. - UNGARIA
Holder: EGIS PHARMACEUTICALS PLC. - UNGARIA
Number: 11983/2019/03
Shelf life: 5 years